AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Trial results of antinicotine vaccine and gene therapy cancer product promising.(Brief Article)
2002 JUL 17 - (NewsRx.com & NewsRx.net) -- Xenova Group plc (XNVA) announced that data from a phase I trial for the antinicotine vaccine, TA-NIC, has shown the vaccine to be safe and well tolerated both systemically and locally and that the vaccine generated a specific antinicotine response.
This double-blind, randomized, placebo-controlled study was designed to assess the safety, tolerability and immunogenicity of the TA-NIC vaccine in both smokers and nonsmokers. The vaccine was administered by intramuscular injection and investigated at two different dose levels in a variety of dosing regimens.
TA-NIC is one of two Xenova antiaddiction product candidates undergoing clinical trials. An anticocaine vaccine, TA-CD, is currently in phase II clinical development.
Speaking at the 64th Annual Scientific Meeting of the College on Problems of Drug Dependence, in Quebec, Canada, Dr. John St. Clair Roberts, Medical Director of Xenova, commented:
"These preliminary results have shown that TA-NIC is both safe and well tolerated in the 60 smokers and nonsmokers who took part in the trial, and that it is capable of generating antibodies which specifically bind to nicotine. We believe ...
- Cantab Reports Interim Financial Results and Increases Products In Clinical...
- Press release article from: PR Newswire September 6, 2000 700+ words
...clinic by mid-year, and two of these, TA-CIN and DISC GMCSF, have begun Phase I trials, with enrollment already completed for TA-CIN. Preclinical development of the third, TA-NIC, continues and is scheduled for completion...
- Cantab Reports 1999 Preliminary Financial Results.
- Press release article from: PR Newswire February 10, 2000 700+ words
...in the US Phase IIa clinical trial of TA-CD. The trial is to be conducted...Three further product candidates, TA-NIC, for nicotine addiction, TA-CIN, for cervical dysplasia, and DISC-GMCSF for cancer immunotherapy are in the...
- Xenova Group plc.
- Press release article from: PR Newswire June 14, 2002 700+ words
...Results of Phase I Trial for TA-NIC First Evaluation...Nicotine Vaccine in Man Disc-Gmcsf Found to Be Safe and Well...anti-nicotine vaccine, TA-NIC, has shown the vaccine...have also shown DISC- GMCSF to have efficacy in models...particularly encouraged that TA-NIC has been shown to...
- Xenova Group plc Third Quarter Results Announcement.
- Press release article from: PR Newswire November 7, 2002 700+ words
...IIa trial for therapeutic vaccine TA-HPV * Patient dosing begins in...anti-cocaine addiction vaccine TA-CD * $63m (43.2m pounds) development...marketing approval in Europe. DISC-GMCSF -- DISC-GMCSF, an innovative immunotherapeutic...
- Xenova Group plc: Preliminary Results for the Year Ended 31 December 2002.
- Press release article from: PR Newswire February 24, 2003 700+ words
...Anti-cocaine addiction vaccine TA-CD starts Phase IIa dose escalation...nicotine addiction vaccine TA-NIC -- Positive results of...trials for anti-HPV vaccine TA-HPV -- Successful conclusion...for gene therapy product DISC-GMCSF -- Potential $63.0m (43...
- Cantab Pharmaceuticals plc: Preliminary Results for the Year Ended December 31,...
- Press release article from: PR Newswire February 19, 2001 700+ words
...open-label Phase IIa trial of TA-HPV, designed to prevent the...be reviewed at six months. * TA-CD, a vaccine to treat cocaine...enrolled into a Phase I trial of TA-CIN, a vaccine to treat cervical...available during H1 2001. * DISC-GMCSF commenced a Phase I tr
- Xenova: Interim Results Announcement 2001.
- Press release article from: PR Newswire August 13, 2001 700+ words
...Topiosomerase prime/boost study) - TA-HSV Inhibitors (XR11576) TA-NIC (with Phase I Lilly Angiogenesis...Research: Celltech - OX40 - DISC-GMCSF, OX40L CTB-Men.B (Autoimmune...Herpes Infectious Disease NIDA - TA-CD - OX40L The implementation...
- Xenova Group plc Anti-Cancer Compound XR11576 Enters Clinical Trials.
- Press release article from: PR Newswire February 5, 2002 700+ words
...Two immunotherapeutic vaccines, TA-HPV and TA-CIN, are undergoing Phase II...dysplasia and a third vaccine, DISC-GMCSF, is being evaluated for the treatment...non-cancer related therapy areas, TA-CD, a vaccine for the treatment...